

## Summary

### Present Status and Progress of Endocrine Nuclear Medicine

Masayuki NAKAJO

*Department of Radiology, Faculty of Medicine, Kagoshima University*

The author reviewed present status and progress of endocrine nuclear medicine including thyroid, parathyroid, adrenocortical, adrenomedullary and somatostatin receptor imaging and also radionuclide therapy of Basedow's disease, metastatic foci of post-operative thyroid cancer and malignant neural crest tumor. Relatively new imaging agents include  $^{99m}\text{Tc}$ -MIBI and  $^{99m}\text{Tc}$ -tetrofosmin for parathyroid imaging

and  $^{111}\text{In}$ -pentetreotide for somatostatin receptor imaging. It is hoped that therapy of malignant neural crest tumors such as metastatic pheochromocytoma and neuroblastoma with  $^{131}\text{I}$ -MIBG and somatostatin receptor imaging will be available in Japan as soon as possible.

**Key words:** Radionuclide imaging, Thyroid, Parathyroid, Adrenal gland, Somatostatin.